For GLP-1 RA trials, percentage of Asians was highest in “Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes” (PIONEER-6) at 19.8% and lowest in “Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes” (REWIND) at 4.4% (24, 27). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.